Dr Robak is a second-year psychiatry resident at Creighton University School of Medicine in Omaha, Nebraska.
Zuranolone for the Treatment of Adults With Major Depressive Disorder
This randomized, placebo-controlled, phase 3 clinical trial showed that a 14-day treatment course of oral zuranolone 50 mg/day in MDD led to significantly greater improvements in depressive symptoms when compared with placebo.